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Abstract
Minimally invasive treatments for hepatocellular carcinoma (HCC) are a cornerstone 
in the management of this challenging disease. For many years, percutaneously guided 
ablative techniques, such as radiofrequency ablation (RFA), cryoablation, and microwave 
ablation (MWA), have successfully treated many different solid malignancies including 
HCC. Since the initial implementation of these ablative techniques, there have been many 
advances in the design, technique, and patient selection as well as investigation into the 
body’s response to treatment. The mechanisms of thermal-based ablative techniques, 
advantages and disadvantages of each technique, subsequent immunologic response fol-
lowing ablation, and advances in care that utilize combination therapy to potentiate the 
immunologic response creating a robust and long-term immunity to HCC are outlined 
in this chapter.
Keywords: hepatocellular carcinoma (HCC), immunotherapy, immunologic, 
response, immune, cancer, carcinoma, oncology, radiofrequency, microwave, ablation, 
cryoablation
1. Introduction
Hepatocellular carcinoma (HCC) is the most rapidly increasing type of cancer in the United 
States due to viral hepatitis and various forms of liver cirrhosis. HCC is resistant to traditional 
chemotherapy and often is not amenable to surgical resection due to factors involving the pri-
mary tumor or patient comorbidities [1, 2]. Thus, minimally invasive therapies for the treat-
ment of malignant liver tumors have become a cornerstone of treatment. These minimally 
invasive techniques, including radiofrequency ablation (RFA), microwave ablation (MWA), 
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and cryoablation (cryo), have been shown to have distinct advantages over traditional treat-
ment methods. These methods are not only able to locally control the malignancy through 
cellular necrosis and apoptosis but also potentially trigger systemic immune responses [3–6]. 
Additionally, these minimally invasive techniques offer other advantages such as lower mor-
bidity, preservation of healthy tissues, lower cost, and decreased hospitalization time relative 
to surgical resection [5]. In this chapter, the mechanisms, advantages, disadvantages, syner-
gism, and immunologic responses to the techniques outlined above are discussed.
2. Radiofrequency ablation
2.1. Overview
Radiofrequency ablation (RFA) is a minimally invasive technique used to thermally ablate 
targeted lesions in a variety of tissues. RFA is performed by percutaneously inserting one or 
more probes using various forms of image guidance, such as computed tomography (CT) or 
ultrasound (US). RFA may also be performed through other approaches such as laparoscopy 
and open surgery. The number of probes used is based on multiple factors such as the size of 
the lesion, the impedance of the targeted region, and surrounding structures such as blood 
vessels and lymphatic channels. In addition to the placement of RFA probes, one or more 
grounding pads are also placed on the patient. These grounding pads are located at a distant 
site from the probes. For example, a common practice is to place multiple grounding pads on 
both thighs when using RFA to ablate lesions located in the liver. Once the placement of the 
RFA probes has been confirmed with image guidance, an alternating current is generated by 
a power source between the probes and the grounding pads. This alternating current creates 
the thermal ablative region by causing ions to oscillate, generating frictional heat. RFA can 
reliably generate temperatures of 60–100°C in the targeted region leading to focal hyperther-
mic injury to the nearby cells. When temperatures reach 60°C or higher, instant cell death 
occurs, and at temperatures above 100°C, charring of surrounding tissues occurs. These two 
temperature points are crucial to the procedure because the operator can be certain that cell 
death has occurred in the regions >60°C, but it is also important to monitor the temperatures 
so that they do not increase too quickly or reach >100°C. If the temperature becomes too high, 
charring of the tissues occurs, which increases the impedance significantly and causes the 
technique to lose efficacy by diminishing the ablative zone substantially [7]. Additionally, at 
temperatures above 110°C, vaporization of the tissues occurs. Vaporization also increases the 
impedance of the tissues limiting the ablative zone [8].
The ablated area with RFA can be divided into three zones: central, transitional, and the 
unaffected surrounding parenchyma [8]. The central zone is the area directly surrounding 
the RFA probe. In this zone, the temperatures are the highest, typically >50–60°C, leading to 
coagulative necrosis of the cells in this region. The cells in this zone immediately undergo 
irreversible injury through protein denaturation of both the cytosolic, nucleic, and mitochon-
drial enzymes leading to coagulative necrosis. In addition to protein denaturation, the cell 
membrane integrity is also compromised. The higher temperatures in the central zone lead 
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to changes in fluid permeability through destruction of the membrane actin filaments. These 
membrane changes result in an intracellular fluid shift and subsequent cytolysis [5, 8].
Cells in the transitional zone are heated through conductive heat transfer from tissues in 
the central zone. This conductive heat transfer produces a sharp temperature gradient with 
average lower temperatures ranging from 40 to 45°C [5]. Cells within the transitional zone 
experience thermal injury, but since temperatures of 50°C are not reached, these cells do not 
undergo immediate cellular death [9]. Rather, the cells’ metabolic processes and DNA repair 
mechanisms are impaired, which trigger specific changes that eventually lead to apoptosis 
or eventual cellular recovery. Other proposed mechanisms of cellular death include ischemia 
from vascular damage, reperfusion injury, and cytokine release and subsequent immunologic 
response to the damaged cells. Due to these changes, a complete response to ablation in this 
region will take several days to fully develop. This region also undergoes reactive hyperemia 
in response to the damage. The combination of hyperemia and increased cellular susceptibil-
ity creates a favorable environment to use liposomal chemotherapeutics. Liposomal chemo-
therapeutics will accumulate in the region due to the hyperemia and have increased activity 
on the already susceptible tumor cells. Since very few of the cells in this region are completely 
denatured, the transitional zone plays a critical role in the immunologic response, which will 
be discussed in more detail [5, 6, 8].
Surrounding parenchyma is not left totally unaffected by RFA. While the cells within this 
zone will not undergo cellular changes, necrosis, or apoptosis, there are several processes that 
will occur. There is an upregulation of various factors, presentation of antigens to antigen-
presenting cells (APCs), and stimulation of the immune system, which will be discussed more 
in depth in later sections. Additionally, hyperemia occurs which can result in reperfusion 
injury [5, 6].
All of the above processes are dependent on a multitude of different factors such as the tumor 
composition, the surrounding parenchyma, the rate at which the energy is applied, and sur-
rounding anatomic structures. The majority of the data on the effects of hyperthermia have 
been generated from literature on low-temperature hyperthermia that was applied uniformly 
over longer periods.
2.2. Patient selection
Traditionally, hepatic resection (HR) has been regarded as the first-line treatment for HCC, 
and RFA was typically reserved for patients with non-resectable disease. However, RFA has 
become a first-line treatment for early-stage HCC in patients with non-resectable disease, 
metastatic disease, recurrent HCC after HR, and for patients who are unable or are unwilling 
to undergo surgery [10]. RFA is best used in patients who have a solitary nodule <5 cm mea-
sured in the greatest dimension or less than three nodules all measuring <3 cm in the greatest 
dimension. RFA is most effective when treating HCC lesions that are ≤2 cm measured from 
the largest dimension. The reason it is more effective in these smaller lesions is that ablation 
margins of >4–5 mm can be easily obtained [1, 10]. Histologic and prospective studies have 
shown that the sensitivity of CT for detecting remnant neoplasm is anywhere between 36 and 
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44% [11, 12]. Thus, the clinician cannot readily rely on imaging to confirm that the lesion has 
been fully treated during or after the procedure making pre-procedure planning and patient 
selection crucial. Meta-analysis and systematic reviews have also shown that the efficacy of 
RFA and HR when used to treat lesions <5 cm is similar. There is no difference in 1-year overall 
survival; however, there is a difference in the 3- and 5-year survival. HR offers greater 3- and 
5-year survival when compared to RFA as well as 1-, 3-, and 5-year disease-free rates. It has 
been postulated that these findings are due to how each treatment method works. With RFA, 
the primary lesion is directly targeted with minimal damage to the surrounding tissues, which 
may leave satellite lesions that would have been removed with HR. Additionally other factors 
come into play with RFA such as the shape and distribution of the ablation zone. However, 
RFA has been shown to have fewer complications during and after the procedure, shorter hos-
pital stays, and is considered safer and less invasive than HR. While HR has a significant role 
in the treatment of HCC, there are limited studies comparing RFA to HR [10, 13, 14]. At the 
current time, it cannot be confirmed which treatment is superior to the other in treating early-
stage HCC. It is up to the treating clinician to determine which treatment is best. RFA should 
be considered as a first-line treatment in specific patients with small solitary lesions <5 cm; 
patients with less than three lesions that are <3 cm; patients with non-resectable, metastatic, or 
recurrent disease; patients who elect for non-operative or a minimally invasive approach; and 
patients who are non-operative due to medical comorbidities [10].
2.3. Advantages and disadvantages of RFA
Of all the thermal ablative techniques for treating HCC, RFA has been the most researched. 
There are many technical advantages using RFA for the treatment of HCC. The most obvious 
advantage of RFA as well as other thermal ablative techniques is the ability to treat a wide 
variety of patients while sparing normal liver parenchyma.
However, an important consideration with RFA and other thermal ablative techniques is the 
“heat sink effect” of surrounding anatomic structures. The heat sink effect is caused when the 
desired ablative region contains or is abutted by larger vessels that result in heat dissipation. 
This dissipation can ultimately lead to temperatures not reaching cytotoxic levels in the lesion 
[15–17]. Animal studies have shown that the heat sink effect is not significant until the ves-
sel diameter is ≥3 mm [15]. Additional studies have shown a clinically significant increase in 
tumor recurrence when abutted by a vessel at least 3 mm in diameter [16]. Another concern is 
damage and thrombosis of surrounding vessels. It has been shown that there is minimal dam-
age and thrombosis to surrounding vessels if the size of those vessels is greater than 3 mm 
[15]. The implication of these studies is that if a lesion contains a vessel greater than 3 mm, the 
RFA probe should be placed close to, but not in, the vessel to achieve the best outcome [15, 
16]. This placement will move the tumor cells surrounding the vessel into the central ablation 
zone increasing the likelihood of cell death without significantly increasing damage to the 
vascular structure.
Other methods to mitigate the heat sink effect have also been studied. One method to over-
come the heat sink effect is to occlude the blood supply to the region being ablated with a 
balloon catheter or gel foam [18]. Since the majority of the blood supply to HCC lesions is 
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derived from the hepatic artery, temporary occlusion of this artery with a balloon catheter 
will reduce the heat sink effect and increase the size of the ablative region. Another method of 
occlusion is embolization of feeding vessels with gel foam. These methods enable the genera-
tion of a larger ablative zone. Risks of hepatic artery occlusion and gel foam embolization do 
exist and should be considered [16].
Injection of NaCl-containing solutions has also been explored to overcome the heat sink effect 
[16, 19–21]. Pre-treatment with hypertonic saline, 5–36%, results in significantly higher tem-
peratures and a significantly larger ablation zone when compared to no pre-treatment [19, 
20]. The NaCl solutions can be injected at any point during the procedure to expand the size 
of the ablation zone [21].
Transarterial chemoembolization (TACE) combined with RFA is another widely studied tech-
nique for overcoming the heat sink phenomenon. Combining these two techniques has mul-
tiple benefits that have been shown in both animal and human models [22–24]. First, TACE 
reduces the amount of conductive cooling by reducing blood flow to the targeted region. 
The reduction in blood flow increases the size of the central ablation zone, thus increasing 
the amount of coagulative necrosis. In addition, the amount of tissue that receives sublethal 
hyperthermia is increased and simultaneously exposed to a chemotherapeutic agent. The 
synergy is created by increased membrane permeability, intratumoral accumulation of the 
pharmacologic agent, and increased drug sensitivity of the cells within the transitional zone 
[5, 6, 8, 24]. Liposomal doxorubicin has been well studied in the setting of liver malignancies 
and is a good choice of chemotherapeutic agent [22, 24]. The wider ablation margin with 
increased volume of both the central and transitional zone and high local concentration of 
chemotherapeutic agent results in destruction of microscopic satellite lesions surrounding the 
lesion consequently improving local control of the tumor [18, 24].
2.4. Immunologic response to RFA
To adequately discuss the immunologic response to RFA, the basic immunologic response 
must first be discussed. The immune system is composed of two basic parts, the innate and 
the adaptive immune systems. Both of these systems work in concert to mount a defense to 
pathogens, such as viruses and bacteria, and prevent unregulated cell growth. The immune 
system is able to recognize and eliminate both dangerous self and non-self cells through a sys-
tem of complex interactions and “danger signals.” However, in HCC and other malignancies, 
the cells evade the immune system through numerous mechanisms [4, 25].
Typically, the first response by the immune system that occurs is by the non-specific or innate 
immune system. The non-specific immune system is composed of natural killer cells (NK), 
mast cells, eosinophils, basophils, macrophages, neutrophils, and dendritic cells (DC). These 
cells are the first to mobilize and produce signals initiating the specific immune response. 
The specific or adaptive immune system is composed of B and T lymphocytes. With co-stim-
ulation from the innate system, the adaptive system generates a robust and lasting immune 
response through the formation of antibodies and memory B and T cells. The basic process 
that must occur to achieve a full immune response is antigen recognition and presentation 
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by antigen-presenting cells (APCs), subsequent recognition of the antigen by T-cells through 
interaction with APCs, cellular interaction generating costimulatory signals, and the presence 
of danger signals [4, 6]. It is important to mention the roles of CD4 or T helper cells (Th) and 
CD8 T cells or cytotoxic T cells (CTLs). In regards to antitumor immunity, the most important 
role of CD4 cells is to assist in the activation and proliferation of CD8 T cells. It is currently 
theorized that a high ratio of CD4:CD8 is important to forming lasting immunity to malig-
nancies because of the role of CD4 cells in stimulating CD8 cells [30]. CD8 T cells have been 
the focus of antitumor immunity due to their ability to recognize MHC I molecules. MHC I 
molecules are used to display intracellular antigens on the surface of cells infected by viruses 
and malignant cells. CD8 cells bind to cells expressing specific MHC I molecule complexes 
and then destroy the targeted cells through the apoptotic cascade [26].
In contrast to HR where the objective is to completely remove the HCC lesion and occa-
sionally remove local lymphoid tissues, minimally invasive techniques such as RFA leave 
necrosed tumor cells and their spilled intracellular materials behind. The retained intracel-
lular materials, which were previously invisible to the immune system, can now act as anti-
gens that trigger local and systemic immune responses to HCC. In addition to the release of 
antigenic material from the remaining necrotic tissues, danger signals, such as DNA, RNA, 
pro-inflammatory cytokines, uric acid, and heat-shock proteins (HSPs), are released. These 
damage-associated molecular pattern molecules (DAMPs) are then picked up by DCs and 
presented to T-cells starting the immune cascade. All of these DAMPs are inflammatory 
mediators and have the potential to trigger a robust tumor suppressing immune response but 
are only released by cells undergoing necrosis. Cells, which undergo apoptosis, may actually 
lead to tolerance if the ratio of apoptosis to necrosis within the lesion becomes too high [4, 25].
One class of DAMP of particular importance to RFA and other thermal ablative techniques 
is the heat shock protein (HSP) family. HSPs have special roles and are involved in protein 
folding, cellular signaling, cellular transport, and survival. HSPs are produced within cells in 
response to thermal injury and play a role as chaperones enabling the refolding of denatured 
proteins. Additionally, HSPs participate in the initiation of the adaptive immune response 
by presenting antigens to DCs, modulating DAMP-induced immune stimulation, and func-
tion as danger signals [25, 27]. HSPs’ ability to chaperone peptides and provide maturation 
signals to dendritic cells causes the ultimate cross-presentation of antigen to CD8+ T cells. 
Independent of the adaptive response, HSPs induce local necrosis through stimulation of 
the innate immune system. HSPs’ ability to efficiently stimulate both the innate and adaptive 
immune system holds great potential; therefore, upregulation of HSPs represents a potential 
approach to eliminate HCC and other malignancies [28].
In patients treated with RFA, there is a decreased response by CD25+ T-regulatory (Treg) cells 
[29]. Treg cells or T suppressor cells, a specific subset of T-cells, are responsible for down-
regulating the immune response. The Treg cell’s role is to prevent autoimmune disease and 
create tolerance to self-antigens. Tregs achieve immunosuppression by downregulating CD4 
and CD8 T cells, thus decreasing the tumoricidal immunologic response. In fact, high levels 
of CD25 T cells are associated with poorer outcomes in patients with malignancy [26]. Thus, 
patients with HCC can benefit from treatments that decrease the number of Treg cells and 
subsequent decreased immune tolerance of malignant cells. Indeed, RFA results in decreased 
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counts of suppressive T cells, but additionally RFA shows increased survival benefit due to 
improved CD8 T-cell counts. The post ablation increase in CD8 T-cells is strongly associated 
with decreased recurrence and increased survival in patients with HCC [30]. Patients who 
will undergo HR or liver transplantation can also benefit from RFA-induced stimulation of 
CD8 cells. One major issue these patients face long term is disease recurrence. Unitt et al. 
showed improved survival in patients who demonstrate strong CD4 and CD8 T cell responses 
after undergoing resection surgery [31]. The response by CD4 and CD8 T cells as well as the 
increase of specific antibodies has been seen weeks to months following RFA [32].
Most of our knowledge about the immune response to RFA is based on animal models and 
small human trials. One of the first studies to show a significant immune response to RFA was 
conducted in 2003. In this animal study, tumors were implanted into rabbits that were then 
either untouched or treated with RFA. The RFA-treated animals showed at least a threefold 
increase in specific T-cell infiltration compared to the untreated animals. The treated animals 
also showed an increase in survival rate. This study suggested that an anticancer immuno-
logic effect could be created through RFA [33]. This study was then further augmented by 
blocking CTLA-4 with monoclonal antibody at the time of RFA. This strongly enhanced anti-
tumor immunity and provided protection against tumor rechallenge. This demonstrated that 
a lasting systemic memory response is achievable with combination therapy. Furthermore, 
a 20-fold increase in specific cytotoxic T-cells (CTLs) was achieved when RFA + blocking 
antibody was used compared to RFA + control antibody demonstrating that the increased 
immune response to RFA can be potentiated [34]. Zerbini et al. were the first to demonstrate 
an increased immunologic response in human subjects. The effect of RFA on 20 patients with 
HCC was studied and found to have a significant increase in tumor-specific T-cell response. 
Circulating T and natural killer (NK) cells showed increased activation and expression of 
specific cytotoxic surface markers. Although an upregulated immune response was dem-
onstrated in these subjects, the effect was not associated with increased protection to HCC 
relapse [35]. Later, Zerbini and colleagues showed that the immunologic effects post RFA are 
dependent on maturation of DCs driven by the release of intracellular debris [36]. In a murine 
urothelial carcinoma model, subtotal RFA was used to induce an immunologic response. In 
response to subtotal RFA, there was an increase in CD4 and CD8 responses and significant 
tumor regression with rechallenge [37].
It is clear that numerous benefits of RFA exist and that there is great potential for targeted 
stimulation of the immune system using RFA in conjunction with immune modulators. 
Nevertheless, the possibility of causing rapid growth of metastases exists [38–40]. Recent 
accounts of RFA and other forms of ablation causing growth of distant metastases have been 
reported. These reports in conjunction with the fact that RFA will induce mediators such as 
cytokines, including interleukin-6 (IL-6) and factors such as hepatocyte growth factor (HGF), 
vascular endothelial growth factor (VEGF), hypoxia-induced factor-1α (HIF-1α), and HSPs, 
all have potential to cause tumor growth locally and distantly [38–42]. It is theorized that dam-
age to the surrounding healthy liver parenchyma and following regeneration is the source of 
the pro-growth factors. Ahmed et al. [40] showed using a rat model that damaging normal 
hepatic tissue with RFA will induce distant tumor growth, which is mediated by VEGF and 
the HGF/c-Met pathway. Interestingly, multiple studies have shown that incomplete ablation 
of HCC will also promote not only distant growth but also local invasion [41, 43–45].
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While increased local and distant growth of tumor cells is a real possibility, there are mul-
tiple studies investigating how to mitigate the pro-growth effects created by RFA. Studies 
have investigated c-Met and VEGF inhibitors to attenuate the tumorigenic effects [38, 40]. 
Additionally, studies have looked at non-specific anti-inflammatory drugs to mitigate the 
effects of RFA-induced inflammation on tumorigenesis. Both aspirin and celecoxib have been 
investigated to prevent tumorigenesis [41, 42]. In animal models, each of these drugs when 
used in conjunction with RFA reduced local inflammation and subsequent effects on distant 
tumor cells. Furthermore, it is crucial to note that while there is information about distant 
tumorigenesis following RFA, clinically RFA has not been shown to worsen survival compared 
to untreated patients and remains an effective first-line treatment in appropriate patients [46].
3. Cryoablation
3.1. Overview
Cryoablation is a thermal ablative technique that has been used since the nineteenth cen-
tury. While other thermal ablative techniques add heat to the surrounding tissue, cryoabla-
tion removes heat. In its earliest form, a salt and ice solution was applied to breast and skin 
cancers. This treatment resulted in decreased pain and lesion size. In its current form, cryoab-
lation is performed similarly to other ablative techniques. It can be used in either a percuta-
neous fashion, with image guidance, or through an open or laparoscopic surgical approach. 
Cryoablation is used to treat numerous types of cancers, but is most commonly used to treat 
liver, kidney, lung, prostate, and breast malignancies [47].
Modern cryoablation requires the use of a specialized cryoprobe that is inserted into the tar-
geted lesion (Figure 1). Once in the desired location, the probe is rapidly cooled beginning 
the freeze cycle for a specified length of time. After the freeze cycle is completed, the probe is 
warmed up to start the thaw cycle. These freeze/thaw cycles are repeated one or more times 
depending on the lesion and preference of the clinician [47]. The mechanism of cooling relies 
on the Joule-Thompson effect that describes how a gas that does not work expands (adiabatic 
expansion) and results in a decrease in temperature [48]. All gases except hydrogen, helium, 
and neon will decrease in temperature when expanded through the Joule-Thompson pro-
cess. Commonly used gases for the freeze cycle are nitrogen and argon. One of these gases is 
pumped into the cryoprobe, and when the gas reaches the distal tip of the probe, the gas is 
throttled and then allowed to rapidly expand to atmospheric pressure. The result is a rapid 
decrease in temperature and cooling of the surrounding tissues via conduction. During the 
freeze cycles, temperatures can reach as low as −160°C, well below the −20 to −40°C required 
to cause cell death [49]. As mentioned above, helium does not undergo this effect, rather than 
cooling when rapidly expanded helium will increase the temperature. For this reason, helium 
is used in the thaw cycle to heat the surrounding tissues [47].
Cryoablation results in direct and indirect cellular injury and death. When the freeze cycle 
begins, the tissues are cooled and ice starts to form in the extracellular space. Since the forma-
tion of ice occurs in the extracellular space before the intracellular space, an osmotic gradient 
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forms. This gradient pulls free water into the extracellular space increasing the solute concen-
tration and dehydrating the cells. The high concentration of solutes intracellularly results in 
damage to enzymes and destabilizes membranes of both intracellular organelles and the cell 
[47]. Intracellular proteins are denatured as well, but return to their original conformation 
once thawing is completed [50]. Cells at the periphery of the ablation will remain intact and 
are not immediately killed by cryoablation. These cells will eventually undergo apoptosis that 
is triggered by damage to organelles [47].
When cells are frozen rapidly, there is no enough time for fluid shifts to occur, and cell death 
occurs via physical damage to organelles and the cellular membrane from intracellular ice 
formation. In both cases, pore formation in the membrane occurs, which allows for fluid 
shifts during the thaw cycle resulting in swelling and rupture [51]. The intracellular fluid 
shift during the thaw cycle occurs since extracellular ice melts before intracellular ice creating 
an osmotic gradient into the cell. It is important to note that intracellular ice will continue to 
grow during the thaw cycle reaching a maximum at −20 to −25°C. This formation of ice dur-
ing the thaw cycle occurs due to the influx of free water. Additionally, the rate of thawing 
determines the amount of cellular death. Rapid thawing will decrease the biocidal effect by 
reducing the amount of intracellular ice formation. A greater degree of cellular death is seen 
in passive thawing when compared to active thawing. The highest degree of necrosis is seen 
with repeated freeze thaw cycles [52].
Indirect injury to cells occurs via vascular damage. During the freeze cycle, the endothelium of 
vessels is damaged, and when thawed, this injury triggers platelet aggregation. This aggrega-
tion leads to thrombosis and subsequent ischemia of the tissues [53]. The ischemia is twofold, 
not only does it lead to cellular death, but it also triggers inflammation. This leads to an influx 
of neutrophils and macrophages to the ablated zone [54]. The entire process can take months to 
complete, resulting in a zone of necrosis surrounded by a peripheral band of neutrophils [47].
3.2. Advantages and disadvantages of cryoablation
The one of the best advantages of cryoablation is the ability to monitor the ablation zone in 
real time. As the ablation proceeds, formation of an ice-ball occurs that is visible on ultrasound 
(US), magnetic resonance (MR), and CT. This occurs because the water molecules undergo a 
Figure 1. Hepatic cryoablation. A cryoablation needle was advanced into a focal hepatic lesion (left), with a resultant 
ice ball visible on CT (asterisk). Follow-up imaging demonstrated a focal defect at the site of the previous lesion (right), 
consistent with a complete ablation.
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phase change and subsequent change in density. For example, during a cryoablation, the 
ablative zone will become hypoattenuating on CT. The leading edge of the ablation marks 
0°C, since this region is where the phase change from liquid to solid is occurring [47].
In contrast to other modalities, such as RFA, each cryoprobe acts independently from the oth-
ers and can be used simultaneously to tailor the shape of the ablation to the tumor. This is in 
sharp contrast to ablating with multiple RF probes where only one probe can be active at a 
time and they must be operated sequentially. Cryoablation additionally offers better pain con-
trol when compared to RFA [47]. The cooling of the tissues can create a level of analgesia not 
offered by hyperthermic ablative techniques. Cryoablation significantly reduces the amount 
of opioids used in the 24 hours following the procedure leading to shorter hospital stays [55]. 
In regards to HCC, it has been shown that RFA can induce ischemia-reperfusion injury of the 
liver resulting in cancer growth. With cryoablation, there is a lower potential for this type of 
injury decreasing the risk of cancer growth [56]. Cryoablation can also be used in patients 
who are candidates for RFA. Patients who are candidates are those with tumors <5 cm, single 
lesions, or multiple lesions <3 cm with a Child-Pugh class A or B liver function [57].
Cryoablation results in a robust inflammatory response following the procedure. This in com-
bination with the fact that the released proteins return to their native conformation produces 
a large potential to create beneficial antitumor immunologic responses. The large amount 
of unaltered tumor antigen coupled with a large inflammatory response creates a scenario 
in which significant numbers of DCs are able to present a large amount of antigen to T cells 
[47, 50, 54]. The potential immunologic response will be discussed in detail later. This robust 
inflammatory response also presents a significant disadvantage, cryoshock [47, 57–59].
Cryoshock is a systemic immune response that leads to hypotension, respiratory distress, 
multiorgan failure, and disseminated intravascular coagulation. Similar reactions are not seen 
in patients treated with hyperthermic ablations. Cryoshock occurs in up to 1% of patients who 
undergo hepatic cryotherapy. Of this 1%, up to 18% of patients can die because of cryoshock 
[57, 58]. Cryoshock is thought to be mediated by the production of cytokine, such as IL-1β, 
IL-6, and tumor necrosis factor (TNF), from the robust immune response created by cryoabla-
tion [47, 57–60]. These are similar to the mediators found in patients with septic shock [59, 65]. 
Cryoshock typically occurs when large volume liver ablations are attempted [47]. An addi-
tional disadvantage of cryoablation is bleeding complications. Typically, these occur when 
performing large ablations within the liver. Frozen tissues are extremely brittle and may frac-
ture leading to significant bleeding. For this reason, the user must be careful to not torque or 
reposition the probes once the ablation has started [61]. Although cryoablation has various 
disadvantages, it has a similar complication rate compared to RFA and remains a relatively 
safe and effective procedure for the treatment of HCC [57–60, 62].
3.3. Immunologic response to cryoablation
For several decades, the immune response to cryoablation has been known. In the 1970s, anti-
tumor antibodies were first seen in humans following cryoablation [63]. Since then, it has 
been shown that cryoablation will induce specific anti-tumor cytotoxic effects post ablation. 
Lymphocytes produced post-ablation show specific affinity for tumor cells when  rechallenged, 
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whereas lymphocytes in patients post HR do not. Reintroduced tumor cells are also rendered 
less effective by the immunologic response [64].
Cryoablation is proven to create a more robust immunological response than hyperthermic 
ablative techniques such as RFA and MWA. Higher DC antigen loading due to hypothermic 
cytotoxicity generates the more robust immunologic response. Increased antigen presentation 
and subsequent heightened immune response are due to two main factors: increased antigen 
in the native conformation and less coagulation in the ablation zone [47]. The hypothermic 
mechanism of cryoablation leads to less regional coagulative effect when compared to hyper-
thermic ablations. This allows the antigens produced by cryoablation to more readily enter 
circulation and regional lymph nodes for presentation to DCs. The ability of cryoablation to 
preserve circulation is beneficial for stimulating the immune system but can be detrimen-
tal. The spilling of tumor antigens into circulation and subsequent cytokine release is also 
believed to be responsible for cryoshock.
Heightened levels of cytokines such as IL-1β, IL-6, TNF-α, and NF-κB are seen after cryoabla-
tion [65, 66]. Cryoablation used on hepatic malignancy will increase the levels of these specific 
cytokines up to 15–25 times more when compared to RFA. Interestingly, Erinjeri et al. found 
that the changes in WBC count increased linearly with ablation size but the levels of IL-6 did 
not [65], suggesting that larger ablative zones could trigger higher tumor-specific immune 
responses without added increased risk for cryoshock. Additionally, this group found that 
the predominant cytokines that are released post cryoablation, IL-6 and IL-10, stimulate a Th2 
response.
According to the Th1/Th2 model, each subset triggers a different type of immunity. Th1 trig-
gers cytotoxic lymphocytes and cellular immunity, whereas Th2 stimulates B-cells and anti-
body production. Signals that stimulate the Th1 response include IL-2, IL-12, IFN-γ, and TNF, 
and the cytokines that trigger the Th2 response include IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 
[65, 67]. In addition, IL-6, which activates NF-κB and STAT3, has been implicated in hepatic 
regeneration and increased tumor regeneration post ablation. Regeneration is mediated by 
NF-κb and STAT3, both of which are activated by IL-6 [65]. Since, both IL-6 and IL-10 are 
increased after not only cryoablation but also hyperthermic ablation, they are potential tar-
gets for adjuvant immunologic therapy. Decreasing IL-6 could potentially increase the Th1 
response (cellular-mediated tumor immunity) and decrease the growth of primary and meta-
static hepatic malignancy post ablation [68].
Immune checkpoint inhibitor therapy, a new oncologic therapy that uses monoclonal anti-
body to target and block the T cell surface receptor CTLA-4, has potential use in combination 
therapy with cryoablation. The function of CTLA-4 is to inhibit self-reactive T-cells in order 
to prevent autoimmune diseases. However, in the case of cancer, it is beneficial for T cells 
to be able to recognize specific “self” cells. It has been shown that blockade of CTLA-4 will 
increase the CD8 T cell response as well as CD4 T cell memory when used as a monotherapy 
or combination immune therapy [69, 70]. Phase 3 trials using ipilimumab, a CTLA-4 block-
ing monoclonal antibody, have showed improved recurrence-free survival when used as an 
adjuvant treatment in patients with high-risk melanoma [71]. Combination cryotherapy with 
CTLA-4 blockade has been studied in prostate cancer. While cryoablation alone has not been 
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shown to mediate the rejection of metastatic lesions, when combined with CTLA-4 blockade, 
it can mediate rejection of metastatic lesions and prevent disease recurrence [72].
While cryoablation has been strongly shown to activate the immune system, the opposite 
has also been seen. Multiple animal models have shown susceptibility to rechallenge and 
increased metastasis post ablation [73–75]. A possible explanation for these results is varia-
tion in the technical factors of cryoablation. Differing animal models, methods of freezing, 
length, number of freeze-thaw cycles, differences in minimum temperature achieved as well 
as differing ablation zone size and position all contribute to different clinical outcome and 
immunologic stimulation or anergy [73]. Sabel et al. established that variation in the technical 
parameters of cryoablation indeed affect the ratio of apoptosis to necrosis and subsequent 
immune response. Sabel et al. investigated the rate of freezing in an animal model using 
either a low or high rate of freezing. They found that a high rate of freezing induced a higher 
amount of necrosis when compared to a low rate of freezing. The high rate induced more dan-
ger signals stimulating a strong anti-tumor response [73]. A high ratio of apoptosis to necrosis 
has been shown to downregulate the immunologic response and even induce anergy [76]. 
When apoptotic cells are presented to DCs, a lower amount of TNF-α, IL-1β, IL-8, IL-10, IL-12, 
and granulocyte macrophage colony-stimulating factor (GM-CSF) produce inhibitory effects 
on these cells [77, 78]. The ablation zone size and percentage of tumor encompassed may 
play a role in the immunologic response. An experiment conducted in a murine metastatic 
liver tumor model demonstrated that smaller volume ablations show a significant decrease 
in metastasis [79].
4. Microwave ablation
4.1. Overview
Microwave ablation (MWA) is a hyperthermic ablative technique that is similar in many ways 
to RFA. MWA was introduced in the 1980s and 1990s and showed potential, but suffered 
from problems controlling the emitted field. There was a relatively high complication rate 
with MWA, thus RFA became the dominant ablative technique [80, 81]. While the early MWA 
systems had higher complication rates, since then newer designs have significantly decreased 
the complication rates. Recent retrospective and prospective studies have proven the efficacy 
and safety of MWA for not only HCC lesions but also other hepatic lesions [82–85].
From a procedural point of view, MWA and RFA are performed similarly under image guid-
ance. The operator guides a MWA antenna toward the targeted lesion using their favored 
imaging modality (Figure 2). Unlike RFA, MWA does not require the use of grounding pads 
to establish an electrical circuit. MWA uses dielectric hysteresis to produce heat. An oscil-
lating field, typically 900–2500 MHZ, is applied forcing polar molecules (such as water) to 
continuously move and realign in the field creating kinetic energy and ultimately raising the 
temperature of the tissue. Microwaves are able to propagate through a variety of tissues, even 
those with low electrical conductivity, high impedance, or low thermal conductivity. This 
makes MWA more versatile [86].
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4.2. Advantages and disadvantages of MWA
MWA has the distinct advantage of being able to penetrate through high impedance tissues, 
meaning that even if charred or desiccated tissues build up near the probe, the field is able to 
penetrate and continue enlarging the ablation zone. Since MWA does not rely on conduction 
of tissue, heat is able to penetrate tissues with a high impedance such as lung or bone [86].
Multiple MWA antennas are able to be used synergistically to enlarge the ablation zone, 
achieve higher temperatures, or concomitantly ablate multiple lesions [87]. While RFA using 
multiple probes requires the probes to be used in series, MWA with multiple antennas can be 
used simultaneously with one power source. Due to the properties of MWA, there is future 
potential use ablating larger lesions than is currently possible.
The peak temperatures achieved in the central zone can readily exceed 100°C. The ability to 
achieve higher temperatures and use multiple probes simultaneously means shorter treat-
ment times and larger area of coagulative necrosis and lethal hyperthermia. Higher tempera-
tures and larger central zone lessen the effect of nearby heat sinks. It has been shown that 
large vessels <10 mm in size will not affect the ablation, making it possible to ablate lesions in 
regions that are not possible with RFA [88].
While MWA has many advantages, its ability to deliver a high amount of energy comes 
with several trade-offs. Coaxial cables have excellent properties for this application and are 
thus used to connect the antenna to the microwave generator. However, the coaxial cables 
used have a large diameter in order to avoid dangerous cable overheating. Larger diameter 
decreases the risk of overheating but becomes cumbersome and inflexible leading to diffi-
culties while manipulating the antennas and performing the procedure [89]. The microwave 
antennas are likewise made using coaxial cable and also suffer from the same problem. In 
order for the antenna to handle higher power levels, the diameter must be increased or an 
active cooling system needs to be employed [86, 89].
Figure 2. Hepatic microwave ablation. Pre-procedure imaging demonstrates a focal HCC lesion at the hepatic dome 
(left, arrow). Two microwave needles were advanced into the lesion, with gas bubbles developing during the ablation 
(middle). Follow-up imaging demonstrates a focal defect without enhancing viable tissue consistent with a complete 
ablation (right).
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Active cooling systems have helped eliminate several problems. They allow a smaller diam-
eter antenna to handle higher power and eliminate the risk of ablating healthy tissues along 
the proximal antenna tract, increase the size of the ablation, increase the amount of power 
delivered, and can prevent the probe from backing out. Various cooling methods have been 
employed from chilled saline to cooling with compressed gas utilizing the Joule-Thomson 
phenomenon [86]. Some newer probes that use the Joule-Thompson phenomenon are able to 
be locked into place by freezing the antenna tract to prevent it from moving or backing out.
Since the primary advantage of MWA is the ability to deliver, a significant amount of power 
safety concerns arises. With MWA, it is harder to predict the size of the ablation zone, which 
can lead to damage of surrounding structures. The shape of the ablation zone produced can be 
relatively thin and long increasing this risk. While problems with MWA exist, currently these 
issues should not limit its use ablating HCC and other lesions in the liver. MWA has been 
proven effective and comparatively safe to RFA when measuring complication rates [82–85].
4.3. Immunologic response to MWA
The immunologic response to MWA is less well characterized compared to other methods 
of ablation, such as RFA and cryoablation. The vast majority of the research regarding the 
immune response and immunologic stimulation has been studied with either RFA or cryoab-
lation. Recently specific immunologic mechanisms and the effects following MWA have been 
studied in more detail. It has been assumed that the immunologic response to MWA is similar 
to the mechanism and response to RFA [90, 91]. Currently, our knowledge about the immune 
response to MWA comes from both animal and clinical trials of various tumor types from 
breast to hepatic carcinomas [92–94].
In regards to patient management and future treatment, the goal of therapy is to generate a 
lasting immune response that results in regression of distant lesions and generate protection 
from disease recurrence. As detailed in previous sections, the aim of treatment is to generate 
specific cytokines triggering the Th1 response and activating the cellular immune system. 
Similar to other ablative techniques, MWA alone is not powerful enough to trigger the desired 
immune response, but holds potential with combination therapy [90, 91].
The specific immune response to MWA in patients with HCC has been analyzed by Zhang 
et al. In their study, 45 patients with HCC treated with MWA had peripheral blood analysis 
following treatment. The results showed significant increases in IL-12 and decreases in IL-4 
and IL-10 [91]. These results are promising since IL-12 is involved in the differentiation of Th1 
cells and generation of cellular immunity. Furthermore, patients showed decreased levels of 
IL-4 and IL-10, which are involved in activation of humoral immunity. While MWA alone is 
not enough to create a significantly different clinical response, the cytokine profile produced 
is advantageous.
Various combination therapies have been studied ranging from OK-432, immunotherapy, 
GM-CSF, and CTLA-4 blockade [92–94]. OK-432, also known as picibanil, is a low virulence 
mixture of Streptococcus pyogenes that has been used as an antitumor agent since 1975 [95]. 
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OK-432 is able to induce pro-inflammatory cytokines and activate the T-cell–mediated immu-
nity. Li et al. demonstrated that MWA and OK-432 used in combination resulted in prolonged 
survival and a strong immunologic response to rechallenge in a murine model of breast can-
cer. The results showed that a dominant Th1 response is generated. The cytokines IL-12, IL-2, 
and IFN-γ were significantly increased with no effect on Th2-type cytokines. Additionally, 
immunohistochemical analysis showed that a predominance of CD8+ T cells infiltrating the 
treated tumors.
Immunotherapy combined with MWA for the treatment of HCC has been investigated in 
both phase I and phase II trials [93, 96]. This combination was shown to increase the absolute 
number of circulating lymphocytes. When analyzed for specific subgroups, patients showed 
increased levels of cytotoxic subsets of T cells and decreased suppressive subsets. Additionally, 
patients treated with immunotherapy had significantly improved liver function. However, 
the disease-free survival and overall survival rate were not significantly improved.
CTLA-4 blockade holds great promise when combined with cryoablation, but could also be 
used in with MWA. CTLA-4 blocking antibodies and GM-CSF combined with MWA were 
shown to induce tumor-specific cellular immune response in a murine model [94]. The combi-
nation of the three resulted in a 90% rejection upon tumor rechallenge and 50% of the animals 
treated showed distant tumor regression. Since both of these drugs are currently available for 
human use, this combination represents one that could be clinically used today.
5. Conclusion
Minimally invasive thermal-based therapy has become a reliable method for the treatment 
of HCC. Many advances in ablative therapy have occurred since their initial implementa-
tion ranging from design to technical implementation. The most promising of these advances 
is combination therapies that create a tumor-specific immunologic response. Combination 
therapy has shown great promise in the treatment and prevention of not only HCC, but also 
other malignancies. There is much more to learn about the immunologic reaction to ablative 
therapy creating an exciting time of investigation and discovery.
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